Regina Graul, Ph.D., Promoted to Chief Executive Officer
Cyclerion Therapeutics (Nasdaq: CYCN) has promoted Regina Graul, Ph.D., to Chief Executive Officer, President, and Board member. Since joining in December 2023, Dr. Graul has focused on reducing operating costs and leading a search and evaluation team to assess multiple business development prospects. The company's Board of Directors expressed confidence in her ability to drive growth and success.
Dr. Graul emphasized her commitment to continuing Cyclerion's evolution, highlighting the formation of a top-notch diligence team currently evaluating promising assets. She acknowledged the challenges ahead but expressed confidence in the company's potential to unlock value for patients and shareholders.
Cyclerion Therapeutics (Nasdaq: CYCN) ha nominato Regina Graul, Ph.D., Amministratore Delegato, Presidente e membro del Consiglio di Amministrazione. Da quando è entrata in azienda a dicembre 2023, la Dott.ssa Graul si è concentrata su ridurre i costi operativi e guidare un team di ricerca e valutazione per esaminare diverse opportunità di sviluppo aziendale. Il Consiglio di Amministrazione ha espresso fiducia nelle sue capacità di promuovere la crescita e il successo.
La Dott.ssa Graul ha sottolineato il suo impegno a continuare l'evoluzione di Cyclerion, evidenziando la creazione di un team di diligence di alto livello che sta attualmente valutando asset promettenti. Ha riconosciuto le sfide future ma ha espresso fiducia nel potenziale dell'azienda di sbloccare valore per i pazienti e gli azionisti.
Cyclerion Therapeutics (Nasdaq: CYCN) ha promovido a Regina Graul, Ph.D., como Directora Ejecutiva, Presidenta y miembro del Consejo. Desde que se unió en diciembre de 2023, la Dra. Graul se ha centrado en reducir los costos operativos y liderar un equipo de búsqueda y evaluación para evaluar múltiples oportunidades de desarrollo comercial. El Consejo de Administración de la empresa expresó confianza en su capacidad para impulsar el crecimiento y el éxito.
La Dra. Graul enfatizó su compromiso con continuar la evolución de Cyclerion, destacando la formación de un equipo de diligencia de alto nivel que actualmente está evaluando activos prometedores. Reconoció los desafíos que se avecinan pero expresó confianza en el potencial de la empresa para desbloquear valor para pacientes y accionistas.
사이클리리온 테라퓨틱스 (Nasdaq: CYCN)가 레지나 그롤 박사를 CEO, 회장 및 이사회 위원으로 승진시켰습니다. 2023년 12월에 합류한 이래로, 그롤 박사는 운영 비용 절감과 여러 비즈니스 개발 가능성을 평가하는 탐색 및 평가 팀을 이끄는 데 중점을 두었습니다. 회사의 이사회는 그녀가 성장과 성공을 이끌 수 있는 능력에 신뢰를 표명했습니다.
그롤 박사는 사이클리리온의 진화를 지속할 것에 대한 자신의 의지를 강조하며, 현재 유망한 자산을 평가하고 있는 최고 수준의 실사 팀의 구성을 강조했습니다. 그녀는 앞으로의 도전 과제를 인정하면서도 회사가 환자와 주주를 위해 가치를 unlocked할 잠재력에 대한 신뢰를 표현했습니다.
Cyclerion Therapeutics (Nasdaq: CYCN) a promu Regina Graul, Ph.D., au poste de Directrice Générale, Présidente et membre du Conseil d'Administration. Depuis son arrivée en décembre 2023, Dr. Graul s'est concentrée sur la réduction des coûts d'exploitation et a dirigé une équipe de recherche et d'évaluation pour évaluer plusieurs opportunités de développement commercial. Le Conseil d'Administration de l'entreprise a exprimé sa confiance dans sa capacité à stimuler la croissance et le succès.
Dr. Graul a souligné son engagement à poursuivre l'évolution de Cyclerion, mettant en avant la formation d'une équipe de diligence de haut niveau qui évalue actuellement des actifs prometteurs. Elle a reconnu les défis à venir, mais a exprimé sa confiance dans le potentiel de l'entreprise à libérer de la valeur pour les patients et les actionnaires.
Cyclerion Therapeutics (Nasdaq: CYCN) hat Regina Graul, Ph.D., zur Geschäftsführerin, Präsidentin und Vorstandsmitglied ernannt. Seit ihrem Eintritt im Dezember 2023 hat Dr. Graul den Fokus auf die Senkung der Betriebskosten gelegt und ein Such- und Bewertungsteam geleitet, um verschiedene Geschäftsentwicklungsmöglichkeiten zu bewerten. Der Vorstand des Unternehmens hat Vertrauen in ihre Fähigkeit geäußert, Wachstum und Erfolg voranzutreiben.
Dr. Graul betonte ihr Engagement für die fortgesetzte Entwicklung von Cyclerion und hob die Bildung eines erstklassigen Due-Diligence-Teams hervor, das derzeit vielversprechende Vermögenswerte bewertet. Sie erkannte die bevorstehenden Herausforderungen an, äußerte jedoch Vertrauen in das Potenzial des Unternehmens, Wert für Patienten und Aktionäre zu schaffen.
- Appointment of experienced leader Regina Graul as CEO, President, and Board member
- Reduction in operating costs to improve financial efficiency
- Formation of expert diligence team for asset evaluation
- Multiple business development prospects under consideration
- None.
CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), today announced that Regina Graul, Ph.D., has been promoted to Chief Executive Officer, President, and member of the Board of Directors. Since Dr. Graul joined Cyclerion as President in early December 2023, she has strengthened all aspects of the company. She has been working closely with the Board of Directors to prioritize building shareholder value by reducing Cyclerion’s operating costs while leading a world-class search and evaluation team, currently triaging multiple business development prospects for which Cyclerion believes it is well suited.
“From the day Regina arrived at Cyclerion, she has done impressive work, quickly assessing the state of the company, challenging the status quo and executing on strategic objectives. She has been the momentum, driving the assessment of new therapies for patients, and looking for ways to enhance value for shareholders,” said Errol DeSouza, Ph.D., Chairperson of Cyclerion Therapeutics. “What Cyclerion has accomplished under her leadership in this short time is notable, and we have great confidence in her ability to steer Cyclerion to a new era of growth and success.”
“I am enthusiastic about stepping into the CEO role and continuing to shepherd the evolution of Cyclerion.” said Dr. Graul. “In partnership with the finance team, we have reduced operational costs while forming a top-notch diligence team – comprised of external experts in their respective fields – currently in advanced stages of conducting promising asset evaluations. With multiple exciting possibilities to choose from, we look forward to building a vibrant new future for Cyclerion.”
Graul continued, “I have a clear view of the amount of work and risks that we are facing, but I believe we have the know-how and grit to build upon Cyclerion’s current foundation to achieve new heights and unlock value for both patients and shareholders.”
About Regina Graul
Dr. Graul has a proven track record of being a catalyst for progress across a variety of positions in the biopharmaceutical industry over the past 20+ years. She is a growth-oriented leader, prioritizing innovation and nurturing a culture of creativity. Prior to her appointment as President in December 2023, Regina was Vice President at EQRx, where she led, in parallel, multiple large cross-functional development teams in oncology. Previously, she served as the head of internal innovation, was a strategic program leader, and partnered with business development to identify licensing opportunities at Cyclerion. Her industry career began at Ironwood Pharmaceuticals (formerly Microbia Inc.) after completing a postdoctorate at MIT, as a medicinal chemist inventing molecules that transitioned to the clinic. She received her Ph.D. in synthetic organic chemistry from Rice University and her B.A. in chemistry from Saint Anselm College.
Forward Looking Statement
Certain matters discussed in this press release are “forward-looking statements”. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should”, “positive”, or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements about pursuing collaborations, licenses, mergers, acquisitions and/or other targeted investments aimed at enhancing shareholder value. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties, including, those under the heading “Risk Factors” in our Annual Report on Form 10-K filed with the SEC on March 5, 2024, and in our Form 10-Q filed with the SEC on August 7, 2024, as well as our subsequent SEC filings. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Contacts
Investor & Media Relations
Email: IR@cyclerion.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1552c3a1-63ad-487f-865d-ae6b5c12211b
FAQ
Who is the new CEO of Cyclerion Therapeutics (CYCN)?
What are the main priorities for Cyclerion Therapeutics (CYCN) under the new CEO?
How has Cyclerion Therapeutics (CYCN) reduced its operational costs?
What is the current focus of Cyclerion Therapeutics' (CYCN) diligence team?
